Revisiting androgens: compelling evidence for their efficacy in ER+ breast cancer

Preclinical research from the University of Adelaide (SA, Australia) has given new evidence to suggest that activation of the androgen receptor in estrogen receptor (ER)-driven breast cancer has a strong anti-tumor effect. Researchers suggest this could have immediate implications for treatment resistant patients. The study was originally due to be presented at the 2020 annual meeting of the Endocrine Society, which was cancelled due to COVID-19 concerns. The research has been published in Nature Medicine, along with a video to explain the study. The role of androgens and estrogens in normal breast development is well established, as is the role...